Abstract Library

#4402 Australasian Gastro-Intestinal Trials Group (AGITG) STOPNET: A randomised study of cessation of somatostatin analogues after peptide receptor radionuclide therapy (PRRT) in mid, hind-gut, and pancreatic neuroendocrine tumours

Introduction: After progressing on somatostatin analogues (SSA), patients with somatostatin receptor positive gastroenteropancreatic (GEP) NETs often receive PRRT. It is unclear whether current practice of continuing SSA after commencing PRRT is beneficial, especially in non-functioning NETs.

Conference:

Presenting Author:

Authors: Burge M, Wyld D, Pattison D, Loree J, Goodwin R,

Keywords: Somatostatin analogue, peptide receptor radionuclide therapy, gastroenteropancreatic, neuroendocrine, non-functioning, cessation, Australasian Gastro-Intestinal Trials Group (AGITG), Canadian Cancer Trials Group (CCTG),

#4330 Clinical and gut microbiota (GM) markers of aggressive carcinoid syndrome (CS)

Introduction: While most patients (pts) with CS present indolent disease (iCS), others have aggressive disease (aCS). Little is known about biomarkers of aCS.

Conference:

Presenting Author: Riechelmann R

Authors: Riechelmann R, Henrique K, Durant L, Iebba V, Derosa L,

Keywords: neuroendocrine tumour, carcinoid syndrome, gut microbiome,

#4306 EVENET: Randomised phase II trial of everolimus 5mg vs. 10mg daily in patients with neuroendocrine tumours

Introduction: Everolimus 10mg PO daily is approved for patients (pts) with advanced G1/G2 neuroendocrine tumours (NET) but is associated with significant toxicity, including 20% of serious infections in real-world pts. In phase I trials, 5mg/day was sufficient to inhibit the mTOR pathway. Retrospective data suggest that 5mg/day is similarly effective to 10mg/day but less toxic.

Conference:

Presenting Author:

Authors: Riechelmann R, Campos A, Durant L, Bulzico D,

Keywords: everolimus, neuroendocrine tumour, dose optimisation, toxicity,

#3877 Short fasting test as a reliable and effective tool to diagnose insulinoma

Introduction: Insulinomas are pancreatic NETs presenting with hypoglycaemia. Current guidelines for its diagnosis require a prolonged fasting test (72 hours), which implies hospitalization and is difficult to perform. It has been reported that up to 85% of insulinomas are diagnosed within a 24h fasting period.

Conference:

Presenting Author: Mikovic N

Authors: Mikovic N, Mazzilli R, Zamponi V, Russo F, Faggiano A,

Keywords: insulinoma, neuroendocrine pancreatic tumor, functioning NET, hypoglycaemia,

#3377 Antisecretory effect of oral targeted therapies in advanced functioning neuroendocrine tumors (the ASSET-NET study)

Introduction: Oral targeted therapies (TTs),everolimus and sunitinib,have demonstrated antitumor activity in patients with advanced progressive neuroendocrine tumors (NETs).

Conference:

Presenting Author:

Authors: Perrier M, Walter T, Do Cao C, Coriat R, Haissaguerre M,

Keywords: functional syndrome, targeted therapy, neuroendocrine tumor, antisecretory effect,